溶血磷脂酰胆碱酰基转移酶 1 表达增加与食管癌患者预后无关。
Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients.
机构信息
General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
出版信息
J Cancer Res Clin Oncol. 2021 Oct;147(10):2879-2884. doi: 10.1007/s00432-021-03686-4. Epub 2021 Jun 19.
INTRODUCTION
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has repeatedly been suggested to be associated with tumorigenesis. To evaluate the role of LPCAT1 in esophageal cancer, LPCAT1 immunostaining was analyzed on a tissue microarray containing samples from esophageal cancer patients.
RESULTS
In benign esophageal tissue, LPCAT1 staining was detectable in low intensities. LPCAT1 staining was increased in malignant as compared to benign esophageal tissue and was found in high intensity in 26.4% of 288 interpretable esophageal adenocarcinomas (EACs) and in 23.2% of 211 squamous cell carcinomas (ESCCs). Increased LPCAT1 staining was linked to undifferentiated tumor grading in both subtypes of EACs and ESCCs (p = 0.0273 and p = 0.0085).
CONCLUSION
However, LPCAT1 was not associated with prognosis of EAC and ESCC patients (p = 0.6838 and p = 0.4695) and thus cannot be considered a prognostic biomarker in esophageal cancers.
简介
溶血磷脂酰胆碱酰基转移酶 1（LPCAT1）多次被认为与肿瘤发生有关。为了评估 LPCAT1 在食管癌中的作用，对包含食管癌患者样本的组织微阵列进行了 LPCAT1 免疫染色分析。
结果
在良性食管组织中，LPCAT1 染色可检测到低强度。与良性食管组织相比，恶性组织中 LPCAT1 染色增加，在 288 例可解释的食管腺癌（EAC）和 211 例鳞状细胞癌（ESCC）中，有 26.4%和 23.2%的患者发现高强度染色。在两种 EAC 和 ESCC 亚型中，LPCAT1 染色增加与未分化的肿瘤分级相关（p=0.0273 和 p=0.0085）。
结论
然而，LPCAT1 与 EAC 和 ESCC 患者的预后无关（p=0.6838 和 p=0.4695），因此不能被认为是食管癌的预后生物标志物。
Zotero 插件